CCR6 antagonist 1 (50 μM, 3 h) blocks the CCL20-induced CD4+ T cell migration. CCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively[1].

CCR6 antagonist 1 (1 mg/kg, s.c., twice daily for 3 days) alleviates TNBS-induced inflammatory responses in mice. CCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects in Zymosan-induced peritonitis mice[1].